Christopher F. Mojcik

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Neal S. Young, Jörg Schubert et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Russell P. Rother, Scott A. Rollins, Christopher F. Mojcik et al. · Nature Biotechnology · 2007 · 752 citations

Allergy, Medicine, Drug Discovery +5

Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Claire Hall, Judith Marsh et al. · New England Journal of Medicine · 2004 · 631 citations · Full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Anita Hill, Peter Hillmen, Stephen J. Richards et al. · Blood · 2005 · 213 citations